IP Verse

Rapid Dissolution Formulation Of Cinacalcet Hcl - EP3395340

The patent EP3395340 was granted to Amgen on Dec 11, 2019. The application was originally filed on Sep 10, 2004 under application number EP18175499A. The patent is currently recorded with a legal status of "Revoked".

EP3395340

AMGEN
Application Number
EP18175499A
Filing Date
Sep 10, 2004
Status
Revoked
Jun 24, 2022
Publication Date
Dec 11, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AECHTERJan 17, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
BIOGARANJan 17, 2020CASALONGAADMISSIBLE
HGFJan 17, 2020-ADMISSIBLE
MAIWALDJan 17, 2020-ADMISSIBLE
ACCORD HEALTHCAREJan 17, 2020TER MEER STEINMEISTER & PARTNERWITHDRAWN
GILLARDJan 16, 2020ELKINGTON AND FIFEADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPEJan 16, 2020SCHLICHADMISSIBLE
HAMM & WITTKOPPJan 16, 2020-ADMISSIBLE
TEVA PHARMACEUTICALSJan 13, 2020ELKINGTON AND FIFEWITHDRAWN

Patent Citations (37) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0933354
DESCRIPTIONUS2002107406
DESCRIPTIONUS5981599
DESCRIPTIONUS6001884
DESCRIPTIONUS6011068
DESCRIPTIONUS6031003
DESCRIPTIONUS6172091
DESCRIPTIONUS6211244
DESCRIPTIONUS6313146
DESCRIPTIONUS6342532
DESCRIPTIONUS6363231
DESCRIPTIONUS6432656
DESCRIPTIONWO0134562
DESCRIPTIONWO9304373
DESCRIPTIONWO9418959
DESCRIPTIONWO9511221
DESCRIPTIONWO9612697
DESCRIPTIONWO9741090
OPPOSITIONEP1663182
OPPOSITIONEP2316442
OPPOSITIONEP2821067
OPPOSITIONEP3260117
OPPOSITIONEP3395338
OPPOSITIONEP3395339
OPPOSITIONEP3395340
OPPOSITIONEP3578175
OPPOSITIONUS2003199497
OPPOSITIONUS2004082588
OPPOSITIONUS5837292
OPPOSITIONUS6211244
OPPOSITIONUS6313146
OPPOSITIONUS9375405
OPPOSITIONWO0137808
OPPOSITIONWO2005034928
SEARCHUS5837292
SEARCHUS6211244
SEARCHUS6313146

Non-Patent Literature (NPL) Citations (78) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BERGE et al., J. Pharm. Sci., (19770000), vol. 66, page 1
OPPOSITION- Ainley Wade, Paul J. Weller, Handbook of Pharmaceutical Excipients, Second Edition, American Pharmaceutical Association, (19940000), pages 483 - 493, XP055671886
OPPOSITION- A. LE HIR, Abrégé de pharmacie galénique formes pharmaceutiques, (19810000), pages 94-95,104 - 105.204-209,205-255, XP055673484
OPPOSITION- Alfonso Gennaro, "Chapter 38, 45", Remington: The Science and Practice of Pharmacy 20th edition, vol. 704, (20000101), pages 704, 858 - 893, XP055672929
OPPOSITION- "Amgen Submitted New Drug Application for Cinacalcet HC1", Amgen News Release, (20030908), XP055674150
OPPOSITION- ANONYMOUS, "Amgen submitted new drug application for Cinacalcet HCI", AMGEN NEWS RELEASE, (20030908), URL: http://www.amgen.com/news/news03/pressRe lease030908a. pdf, (20050112), XP002313388
OPPOSITION- Anonymous, "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", ClinicalTrials.gov /NCT00042653/, (20020806), URL: https://clinicaltrials.gov/ct2/show/NCT00042653, XP055671896
OPPOSITION- Anonymous, "Chemistry Review(s)", Center for Drug Evaluation and Research Application Number: 21-688, page 22pp, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Chemr.pdf, XP055671894
OPPOSITION- Anonymous, "Cinacalcet", Drugbank Internet printout, (20200117), pages 1 - 8, XP055863023
OPPOSITION- Anonymous, "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations", U.S. Food and Drug Administration /FDA/, URL: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021688&Appl_type=N
OPPOSITION- Anonymous, "Super Disintegrants : Characterization and function", Encyclopedia of pharmaceutical technology, (20010101), vol. 20, no. 3, pages 269 - 293, XP055863016
OPPOSITION- Anonymous, "The theory and practise of Industrial Pharmacy", LEA & Febiger Varghese, (19870101), pages 171 - 301-303, XP055863010
OPPOSITION- Anonymus, "Clinical Pharmacology and Biopharmaceutics Review. Application Number 21-688", Center for Drug Evaluation and Research., (20030905), pages 1 - 53, XP055673474
OPPOSITION- Anonymus, "NDA 21-688 Sensipar 30, 60, 90 mg Tablets", Chemistry reviews, Application number 21-688. Center for drug evaluation and research, (20040201), XP055677936
OPPOSITION- "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", (20020806), ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT00042653, (20200226), XP055671896
OPPOSITION- AULTON M.E, Pharmaceutics: The Science of Dosage Form Design, New York, (19880000), pages 311 - 312, XP055673921
OPPOSITION- AULTON, Pharmaceutics: The Science of Dosage Form Design, (20020000), pages 404 - 408, XP055671888
OPPOSITION- "CHAPTER 1: Preformulation Testing", Pharmaceutical Dosage Forms: Tablets, (19890000), pages 1 - 73, XP009184711
OPPOSITION- "Chapter 45 Oral Dosage Forms, section Disintegrants", Remington - The Science and Practice of Pharmacy, (20000000), vol. 1, page 862, XP055673973
OPPOSITION- Chemistry Review- Application 21-688
OPPOSITION- Decision LG Dusseldorf 4CO 24/20- 3 July 2020 (2020-07-03)
OPPOSITION- Decision LG MUNCHEN 21 O 11.642- 4 November 2020 (2020-11-04)
OPPOSITION- Decision OLG Dusseldorf 2U 32/20- 4 March 2021 (2021-03-04)
OPPOSITION- Decision OLG MUNCHEN 6U 6971/20- 25 March 2021 (2021-03-25)
OPPOSITION- Declaration of Professeur Philip GOULD and references
OPPOSITION- Deodatt A Wadke, "Chapter 1 - Preformulation Testing", Deodatt A Wadke, LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets, Volume 1, 2nd ed,, (19890000), pages 1 - 24, XP055416092
OPPOSITION- "Dissolution", Remington - The Science and Practice of Pharmacy, (20000000), vol. 1, pages 657 - 658, XP055674036
OPPOSITION- "Drug Approval Package for SensiparTM (Cinacalcet HCI", Tablets, URL: accessdata.fda.gov
OPPOSITION- Eugene F. Fiese et al, "Preformulation", The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870101), pages 171 - 303, XP055671875
OPPOSITION- Eugene F. Fiese, Timothy A. Hagen, "Preformulation", Eugene F. Fiese, Timothy A. Hagen, Leon Lachman, Herbert A Lieberman and Joseph L Kanig, The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870000), pages 171-197, 298 - 303, XP055671875
OPPOSITION- Extract from the Orange Book : Approved Drug Products with Therapeutic Equivalence Evaluations
OPPOSITION- "Extracts - Microycrystalline Cellulose, Crospovidone, Pregelatinized Starch", Handbook of Pharmaceutical Excipients, pages 84 - 87,143-144,491-493, XP055673640
OPPOSITION- FDA DRUG APPROVAL PACKAGE. SENSIPAR Tablets Application number 021688, (20040507), XP055673613
OPPOSITION- Fiese et al., "8 Preformulation", The theory and practice of industrial pharmacy, (1987), pages 171 - 197, 298-303, XP055671875
OPPOSITION- Fred Bandelin, Shangraw, "Chapter 3: Compressed Tablets by Wet Granulation and Chapter 4: Compressed Tablets by direct Compression", Pharmaceutical Dosage Forms: Tablets, (19900101), vol. 1, pages 131 - 246, XP055678006
OPPOSITION- "Gastrointestinal Absorption - Physicochemical Considerations", Milo Gibaldi, Biopharmaceutics and Clinical Parmacokinetics fourth edition, page 51, XP055355462
OPPOSITION- GIBALDI, Biopharmaceutics and Clinical Pharmacokinetics, (19910000), page 51, XP055677922
OPPOSITION- Gibaldi, "Biopharmaceutics and Clinical Pharmacokinetics. Passage", LEA&FEBIGER, (19910101), page 51, XP055677922
OPPOSITION- GIBALDI, "Gastrointestinal Absorption - Physicochemical Considerations", Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, (19910000), page 51, XP055355462
OPPOSITION- GOODMAN WILLIAM G et al., "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (20020400), vol. 13, no. 4, ISSN 1 046-6673, pages 1017 - 1024, XP002313387
OPPOSITION- GOODMAN WILLIAM G et al., "The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism", Journal of the American Society of Nephrology, vol. 13, no. 4, pages 1017 - 1024, XP002313387
OPPOSITION- J.C CHAUMEIL, "Micronisation : a method for improving the bioavailability of poorly soluble drugs", Meth Find Clin. Pharmacol., (19980000), vol. 20, pages 211 - 215, XP009048140
OPPOSITION- Joseph P. Remington, "Dissolution", Joseph P. Remington, Gennaro Alfonso R., Remington: the science and practice of pharmacy, Easton, Pennsylvania, Mack Publishing Company, (19950101), page 2pp, 595, ISBN 978-0-912734-04-0, XP055282825
OPPOSITION- Kathleen M Lee, "Unit 7.3: Overview of Drug Product Development", Current Protocols in Pharmacology, (20010000), pages 7.3.1 - 7.3.10, XP055319345
OPPOSITION- Kathleen M. Lee, "Unit 7.3: Overview of Drug Product Development", Current Protocols in Pharmacology, (20010101), pages 7.3.1 - 7.3.10, XP055319345
OPPOSITION- Lachman, L. et al, The Theory and Practice of Industrial Pharmacy, third edition, Varghese Publishing House, (19870101), pages 189, 324 - 328, ISBN 978-0-8121-0977-1, XP055673914
OPPOSITION- Leon Lachman, Et Al, "The Theory and Practice of Industrial Pharmacy, third edition", The Theory and Practice of Industrial Pharmacy, third edition, Lea & Febiger, (19860101), pages 189, 321 - 324-329, XP055673418
OPPOSITION- L. LACHMAN et al., The theory and Practice of Industrial Pharmacy, (19870000), pages 324 - 328, XP055673914
OPPOSITION- M H Rubinstein, "Tablets", M H Rubinstein, AULTON, Pharmaceutics: The Science of Dosage Form Design, (19880000), pages 304 - 305, XP055673887
OPPOSITION- Michael E. Aulton, Pharmaceutics: The Science of Dosage Form Design, Second Edition, Spain, Elsevier, (20020000), pages 113-138, 397 - 440, XP055671888
OPPOSITION- Milo Gibaldi, Biopharmaceutics and Clinical Pharmacokinetics, fourth edition,, Lea& Febiger, (19910000), page 51, XP055282823
OPPOSITION- Raymond C. Rowe, Et Al, "Cellulose, Microcrystalline / Starch", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS, (20030529), pages 108 - 603-611, XP055673426
OPPOSITION- Raymond C Rowe Et Al.,, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Sixth Edition, Pharmaceutical Press, (20090000), pages 2pp, 129-131,185,186,208,404,581,582,691 - 692, XP055671872
OPPOSITION- REMINGTON, "The Science and Practice of Pharmacy", (20000000), vol. 704, pages 858 - 893, XP055672929
OPPOSITION- RITSCHEL ET AL.: "Die Tablette", 2002, pages 332 - 335, XP055673487
OPPOSITION- RITSCHEL ET AL., DIE TABLETTE, 2002, pages 332 - 335, XP055673487
OPPOSITION- ROWE et al., Handbook of Pharmaceutical Excipients, (20030529), pages 108 - 111; 603-611, XP055678380
OPPOSITION- Rudnic et al., "Chapter 45: Oral Solid Dosage Form", Remington: The Science and Practice of Pharmacy, (2000), pages 858 - 893, XP002987340
OPPOSITION- Rudolf Voigt, "Tabletten", PHARMAZEUTISCHE TECHNOLOGIE : FÃœR STUDIUM UND BERUF, Stuttgart, Deutscher Apotheker Verlag, (20000101), pages 163 - 187, XP055673408
OPPOSITION- S G Proudfoot, "Factors influencing bioavailability: factors influencing drug absorption from the gastrointestinal tract", S G Proudfoot, MICHAEL AULTON, Pharmaceutics :The Science of Dosage Form Design, (19880000), pages 135,156 - 157, XP055673473
OPPOSITION- U. V. Banakar, "Factors That Influence Dissolution Testing", Pharmaceutical Dissolution Testing, (19920101), pages 136 - 145, ISBN 978-0-8247-8567-3, XP055308585
OPPOSITION- "Wet granulation", Remington - The Science and Practice of Pharmacy, (20000000), vol. 1, no. 20th Edition, pages 865 - 869, XP055674027
OPPOSITION- L. D. Quarles, et al.,, "The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (20030000), vol. 14, pages 575 - 583, XP055671891
OPPOSITION- QUARLES, L.D. et al., "The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease", Am Soc Nephrol, (20030300), vol. 14, pages 575 - 583, XP055671891
OPPOSITION- "Super Disintegrants: Characterization and Function", Swarbrick J; Et Al, Encyclopaedia of Pharmaceutical Technology. Vol 20,, Marcel Dekker, pages 269 - 293, XP055512903
OPPOSITION- Swarbrick J., Et Al, "Super Disintegrants: Characterization and Function", Encyclopaedia of Pharmaceutical Technology. Vol 20, Marcel Dekker, (20010101), pages 269 - 293, XP055512903
OPPOSITION- FRANCE SCHINI et al., "Cinacalcet HC1: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin. Investig. Drugs, (20030000), vol. 12, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCE SCHINI et al., "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin. Investig. Drugs, (20030000), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCESCHINI et al., "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin. Investig. Drugs, (20030000), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCE SCHINI et al., "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin Investig Drugs, (20030800), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 21, XP009083254
OPPOSITION- FRANCE SCHINI et al., "Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin. Investig. Drugs, (20030000), vol. 12, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCE SCHINI, N et al., "Cinacalcet HC1 : a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert opin. Investig. Drugs, (20030000), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCESCHINI N. et al, "CINACALCET HCI: A CALCIMIMETIC AGENT FOR THE MANAGEMENT OF PRIMARY AND SECONDARY HYPERPARATHYROIDISM", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK , (20030101), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, ISSN 1354-3784, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCESCHINI N; JOY M S; KSHIRSAGAR A, "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opinion on Investigational Drugs,, (20030812), vol. 12, no. 8, pages 1413 - 1421, XP009083254
OPPOSITION- GISSINGER D; STAMM A, "A Comparative Evaluation of the Properties of some Tablet Disintegrants", Drug Development and Industrial Pharmacy, (19800000), vol. 6, no. 5, pages 511 - 536, XP008063508
SEARCH- ANONYMOUS, "Amgen submitted new drug application for Cinacalcet HCI", (20030908), AMGEN NEWS RELEASE, URL: http://www.amgen.com/news/news03/pressRelease030908a.pdf, (20050112), XP002313388 [Y] 1-15 * the whole document *
SEARCH- ANONYMOUS, "NPS-Drug Development: Product Develpment Pipeline", (20030908), INTERNET ARTICLE, URL: www.npsp.com/drug_development/pipeline.php, (20050112), XP002313391 [A] 1-15 * the whole document *
SEARCH- GOODMAN WILLIAM G ET AL, "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN. APR 2002, (200204), vol. 13, no. 4, ISSN 1046-6673, pages 1017 - 1024, XP002313387 [Y] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents